{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:34:45Z","timestamp":1777880085085,"version":"3.51.4"},"reference-count":45,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Infection"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>While isavuconazole (ISA) has demonstrated non-inferiority to voriconazole (VCZ) for invasive aspergillosis (IA) in clinical trials, real-world comparisons are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To compare treatment completion, adverse events, hospitalizations, and healthcare costs in patients treated with VCZ versus ISA for IA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective cohort study using Merative MarketScan claims data (2017\u20132020).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Adults (\u2a7e18\u2009years) diagnosed with IA (International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes) who received VCZ or ISA monotherapy were included. Treatment completion was defined as \u2a7e42\u2009days of therapy. Descriptive statistics and logistic regression were used to assess outcomes and predictors of antifungal selection, adverse events, hospitalizations, and treatment completion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 335 patients, 84% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009282) received VCZ and 16% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200953) received ISA. Baseline characteristics were comparable, although the VCZ group had higher Medicaid enrollment, and the ISA group had more patients with malignancy. Treatment completion rates were comparable (92% each,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20091), as were median treatment durations (VCZ: 120\u2009days, ISA: 112\u2009days,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.95). Adverse event rates were not significantly different (VCZ: 49%, ISA: 60%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.18), but CNS-related events occurred more frequently with ISA (16% vs 9%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.32). VCZ was associated with lower outpatient pharmacy costs (median $1,596.68 vs $11,000.66,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and total hospitalization costs (median $40,681.89 vs $121,545.89,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.01). Malignancy was associated with lower odds of receiving VCZ (OR 0.30,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.001), and younger age predicted higher odds of treatment incompletion (OR 0.97,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.035). Female sex was associated with increased adverse event risk. Notably, VCZ use was not associated with increased adverse events or treatment incompletion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>VCZ was prescribed five times more frequently than ISA for IA, despite similar treatment durations and completion rates. VCZ was associated with lower costs and did not increase the risk of adverse events or treatment discontinuation. These findings suggest that VCZ remains commonly used and potentially more cost-effective treatment option for IA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20499361251347778","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T12:22:28Z","timestamp":1751026948000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Voriconazole versus isavuconazole for invasive aspergillosis: a retrospective analysis in a medically insured U.S. population (2017\u20132020)"],"prefix":"10.1177","volume":"12","author":[{"given":"Sophea","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Medical Center, Navicent Health, 777 Hemlock Street, Macon, GA 31201, USA"},{"name":"Research was completed during post graduate training at Phoebe Putney Memorial Hospital and the University of Georgia College of Pharmacy in Albany, GA 31701, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Leigh","family":"Stoudenmire","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Phoebe Putney Memorial Hospital, Albany, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology &amp; Biostatistics, University of Georgia College of Public Health, Athens, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duna","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of Georgia Franklin College of Arts and Sciences, Athens, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7363-8652","authenticated-orcid":false,"given":"Andr\u00e9s F.","family":"Henao-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Colorado, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-0195","authenticated-orcid":false,"given":"Daniel B.","family":"Chastain","sequence":"additional","affiliation":[{"name":"Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, 1000 Jefferson Street, Albany, GA 31701, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw444"},{"key":"e_1_3_4_3_2","unstructured":"CDC. Aspergillosis https:\/\/www.cdc.gov\/fungal\/diseases\/aspergillosis\/index.html (2021 accessed 10 October 2022)."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00583-2015"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.002"},{"key":"e_1_3_4_7_2","unstructured":"Vfend (voriconazole) [package insert]. New York United States: Pfizer Inc. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=12292 (2024 accessed 20 December 2024)."},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt508"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-017-1042-z"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.286-293.2006"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.05.037"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0443-1"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186422"},{"key":"e_1_3_4_14_2","unstructured":"Cresemba (isavuconazonium sulfate) [package insert]. Northbrook IL: Astellas Pharma US Inc. https:\/\/www.astellas.us\/docs\/cresemba.pdf. (2023 accessed 20 December 2024)."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac394"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S150253"},{"key":"e_1_3_4_17_2","unstructured":"Pfizer. Vfend (voriconazole) [package insert]. U.S. Food and Drug Administration website https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021266s039 021267s050 021630s029lbl.pdf (2010 accessed October 2022)."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.1422"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-10627-w"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00721-23"},{"key":"e_1_3_4_22_2","article-title":"Epidemiological trends and clinical outcomes of cryptococcosis in a medically insured population in the United States: a claims-based analysis from 2017 to 2019","volume":"11","author":"Chastain DB","year":"2024","unstructured":"Chastain DB, Zhang Q, Chen X, et al. Epidemiological trends and clinical outcomes of cryptococcosis in a medically insured population in the United States: a claims-based analysis from 2017 to 2019. Ther Adv Infect Dis 2024; 11: 20499361241244967.","journal-title":"Ther Adv Infect Dis"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13189"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-019-00267-4"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13013"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12885"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-023-00727-z"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.10.010"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-019-0311-3"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-2575-1530"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1292163"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-019-00603-6"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H671"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2391492"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13157"},{"key":"e_1_3_4_36_2","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapya","volume":"68","author":"Norris AH","year":"2018","unstructured":"Norris AH, Shrestha NK, Allison GM, et al. 2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapya. Clin Infect Dis 2018; 68: e1\u2013e35.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0297-8"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106711"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac196"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10071-24471"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01511-20"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae037"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3683-2"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0299056"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5658"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1086\/524324"}],"container-title":["Therapeutic Advances in Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361251347778","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20499361251347778","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361251347778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:01:32Z","timestamp":1777593692000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20499361251347778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":45,"alternative-id":["10.1177\/20499361251347778"],"URL":"https:\/\/doi.org\/10.1177\/20499361251347778","relation":{},"ISSN":["2049-9361","2049-937X"],"issn-type":[{"value":"2049-9361","type":"print"},{"value":"2049-937X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"article-number":"20499361251347778"}}